The deadly nature of most pancreatic tumors is well known. Less than 10% of patients with pancreatic ductal adenocarcinoma, or PDA, will survive five years past diagnosis. Recent molecular analyses of PDA has shown that a patient’s prognosis changes depending on their tumor’s molecular characteristics. One subtype of PDA, dubbed quasi-mesenchymal PDA, or QM-PDA, has the worst prognosis of all.
A new research grant enables pancreatic cancer researcher Dr. Sita Kugel to tackle this challenge.
“There is a clear unmet need for developing our understanding of this subset as well as novel therapies,” said Kugel, a scientist at Fred Hutchinson Cancer Research Center.
